SAB Biotherapeutics, Inc.
SABSW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $10.5K in total; no superinvestor holds it.
Other share classesSABS
Q4 2022 vs. Q3 2022
How the institutions holding SAB Biotherapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 16 | 13 | −3 |
| Shares | 1.78M | 1.70M | −83.9K (−4.7%) |
| Value | $84.0K | $57.9K | −$26.1K (−31.1%) |
New holders (1)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| GWM Advisors LLC | 1,072 | $0 | 0.00% |
Sold out (4)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Citadel Advisors LLC | 19,905 | $1.00K |
| HRT Financial LP | 23,756 | $1.00K |
| UBS Group AG | 5,606 | $0 |
| Radcliffe Capital Management, L.P. | 38,927 | – |